Targeting innate immune pathways for cancer immunotherapy.
IL-1
STING
TLRs
Toll-like receptors
anti-tumor immunity
cGAS
cancer vaccines
dendritic cells
inflammasomes
innate immunity
pattern recognition receptors
Journal
Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918
Informations de publication
Date de publication:
10 10 2023
10 10 2023
Historique:
received:
01
05
2023
revised:
28
06
2023
accepted:
26
07
2023
pmc-release:
10
10
2024
medline:
26
10
2023
pubmed:
14
9
2023
entrez:
13
9
2023
Statut:
ppublish
Résumé
The innate immune system is critical for inducing durable and protective T cell responses to infection and has been increasingly recognized as a target for cancer immunotherapy. In this review, we present a framework wherein distinct innate immune signaling pathways activate five key dendritic cell activities that are important for T cell-mediated immunity. We discuss molecular pathways that can agonize these activities and highlight that no single pathway can agonize all activities needed for durable immunity. The immunological distinctions between innate immunotherapy administration to the tumor microenvironment versus administration via vaccination are examined, with particular focus on the strategies that enhance dendritic cell migration, interferon expression, and interleukin-1 family cytokine production. In this context, we argue for the importance of appreciating necessity vs. sufficiency when considering the impact of innate immune signaling in inflammation and protective immunity and offer a conceptual guideline for the development of efficacious cancer immunotherapies.
Identifiants
pubmed: 37703879
pii: S1074-7613(23)00331-X
doi: 10.1016/j.immuni.2023.07.018
pmc: PMC10591974
mid: NIHMS1929264
pii:
doi:
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2206-2217Subventions
Organisme : NIAID NIH HHS
ID : R37 AI116550
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK034854
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007477
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI116550
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI167993
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests J.C.K. consults and holds equity in Corner Therapeutics, Larkspur Biosciences, and Neumora Therapeutics. J.C.K. is listed as an inventor on patents filed by Boston Children’s Hospital on the use of novel dendritic cell stimuli in a therapeutic setting. None of these relationships influenced this study.
Références
Cell. 2011 Dec 9;147(6):1212-5
pubmed: 22153065
Sci Transl Med. 2015 Apr 15;7(283):283ra52
pubmed: 25877890
J Biol Chem. 2004 May 28;279(22):23214-22
pubmed: 15054093
Cell Rep. 2015 May 19;11(7):1018-30
pubmed: 25959818
Cancer Cell. 2018 Sep 10;34(3):361-378
pubmed: 30216189
Clin Cancer Res. 2018 Oct 15;24(20):4937-4948
pubmed: 29950349
Cancer Cell. 2017 May 8;31(5):711-723.e4
pubmed: 28486109
J Immunol. 2011 May 1;186(9):5142-50
pubmed: 21441457
Blood. 2009 Jun 4;113(23):5703-10
pubmed: 19190242
Nat Rev Mol Cell Biol. 2022 Apr;23(4):286-301
pubmed: 34815573
Immunol Rev. 2010 Nov;238(1):76-92
pubmed: 20969586
Nat Med. 2019 May;25(5):814-824
pubmed: 30962585
Nat Rev Immunol. 2003 Feb;3(2):133-46
pubmed: 12563297
Mol Immunol. 2020 Jul;123:64-73
pubmed: 32422416
J Exp Med. 2020 Jan 6;217(1):
pubmed: 31611248
Science. 2016 Jun 3;352(6290):1232-6
pubmed: 27103670
Immunity. 2013 Dec 12;39(6):1003-18
pubmed: 24332029
Immunol Res. 2014 Aug;59(1-3):12-22
pubmed: 24847763
Cancer Gene Ther. 2000 Oct;7(10):1365-74
pubmed: 11059695
J Biol Chem. 2016 Jan 15;291(3):1123-36
pubmed: 26555265
ChemMedChem. 2018 Oct 8;13(19):2057-2064
pubmed: 30079976
Urol Oncol. 2008 Jul-Aug;26(4):341-5
pubmed: 18593617
Clin Cancer Res. 2017 Aug 15;23(16):4556-4568
pubmed: 28468947
Immunity. 2019 Mar 19;50(3):600-615.e15
pubmed: 30824325
Cancer Res. 2016 Apr 15;76(8):2137-52
pubmed: 26951929
Nat Commun. 2018 Aug 9;9(1):3185
pubmed: 30093707
Nature. 2004 Jan 8;427(6970):154-9
pubmed: 14712275
J Exp Med. 2011 Sep 26;208(10):1989-2003
pubmed: 21930769
Br J Cancer. 2006 Apr 10;94(7):1029-34
pubmed: 16598185
Cell Rep. 2020 Nov 17;33(7):108381
pubmed: 33207188
Oncoimmunology. 2017 Nov 27;7(3):e1395126
pubmed: 29399392
Front Endocrinol (Lausanne). 2021 Mar 15;12:626842
pubmed: 33790857
Oncogene. 2018 Jan 25;37(4):439-449
pubmed: 28967901
J Immunol. 2005 Apr 1;174(7):4070-80
pubmed: 15778365
Br J Cancer. 2022 Sep;127(5):785-787
pubmed: 35739301
Cancer Lett. 2020 Jan 28;469:173-185
pubmed: 31629935
Cold Spring Harb Perspect Biol. 2015 Jan 29;7(5):
pubmed: 25635046
Immunity. 2014 Nov 20;41(5):843-52
pubmed: 25517616
Eur J Immunol. 2018 Apr;48(4):584-592
pubmed: 29274245
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33020242
Int J Cancer. 2005 Sep 20;116(5):726-33
pubmed: 15828050
Mol Cancer. 2020 Aug 27;19(1):133
pubmed: 32854711
Nat Biotechnol. 2018 Apr;36(4):346-351
pubmed: 29505028
J Immunol. 2005 Apr 15;174(8):4465-9
pubmed: 15814665
Cell. 2020 Mar 19;180(6):1044-1066
pubmed: 32164908
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14046-51
pubmed: 18780793
Nat Med. 2009 Oct;15(10):1170-8
pubmed: 19767732
Cold Spring Harb Symp Quant Biol. 1999;64:429-35
pubmed: 11232318
EMBO Mol Med. 2014 Sep 17;6(10):1294-311
pubmed: 25231413
Cancer Res. 2002 May 15;62(10):2937-41
pubmed: 12019175
J Immunol. 1979 Jun;122(6):2167-72
pubmed: 312860
Oncology. 2006;70(4):245-54
pubmed: 17047396
Blood. 2011 Nov 3;118(18):4829-40
pubmed: 21908421
Nat Commun. 2020 Oct 27;11(1):5415
pubmed: 33110069
Immunol Cell Biol. 2007 Aug-Sep;85(6):446-57
pubmed: 17667935
Nature. 2020 Aug;584(7822):624-629
pubmed: 32788723
Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7119-24
pubmed: 19359475
Biochem Biophys Res Commun. 2005 Apr 1;329(1):40-5
pubmed: 15721270
Annu Rev Immunol. 2002;20:197-216
pubmed: 11861602
Front Immunol. 2021 Jan 27;11:621931
pubmed: 33584721
Nature. 2018 Jan 25;553(7689):467-472
pubmed: 29342134
Cancer Res. 2006 Mar 15;66(6):3205-13
pubmed: 16540672
Cancer Immunol Immunother. 2015 Nov;64(11):1461-73
pubmed: 26275446
Nature. 2016 Jul 06;535(7610):153-8
pubmed: 27383986
Semin Immunol. 2021 Feb;52:101481
pubmed: 34023170
PLoS One. 2020 Feb 6;15(2):e0227940
pubmed: 32027657
Cancer Immunol Res. 2014 Dec;2(12):1199-208
pubmed: 25300859
Br J Cancer. 2013 Sep 3;109(5):1100-8
pubmed: 23922113
Nat Rev Immunol. 2015 Jul;15(7):405-14
pubmed: 26027717
Clin Cancer Res. 2004 Apr 15;10(8):2891-901
pubmed: 15102698
Biochem Biophys Res Commun. 2004 Apr 23;317(1):68-76
pubmed: 15047149
Int J Mol Sci. 2021 Aug 03;22(15):
pubmed: 34361107
Immunity. 2018 Jan 16;48(1):35-44.e6
pubmed: 29195811
Nature. 2008 Jun 19;453(7198):1122-6
pubmed: 18496530
PLoS One. 2012;7(12):e51618
pubmed: 23284726
Nature. 2019 Oct;574(7776):45-56
pubmed: 31578484
Nature. 2006 Apr 6;440(7085):808-12
pubmed: 16489357
Cancer Res. 1998 Feb 1;58(3):380-3
pubmed: 9458075
Nat Med. 2013 Jan;19(1):57-64
pubmed: 23202296
Cancer Cell. 2023 Mar 13;41(3):620-636.e9
pubmed: 36917954
Methods Mol Biol. 2016;1403:57-84
pubmed: 27076125
Cancer Gene Ther. 2006 Apr;13(4):393-405
pubmed: 16224496
Nature. 1982 Apr 22;296(5859):754-7
pubmed: 6803172
Science. 2013 Jan 18;339(6117):328-32
pubmed: 23329049
Nature. 1980 Feb 14;283(5748):664-6
pubmed: 6965520
Cell. 2017 May 4;169(4):750-765.e17
pubmed: 28475900
Cancer Cell. 2014 Nov 10;26(5):638-52
pubmed: 25446897
Blood. 2010 Nov 4;116(18):3494-504
pubmed: 20696947
J Immunol. 2002 Jul 1;169(1):469-75
pubmed: 12077278
J Exp Med. 2019 Nov 4;216(11):2619-2634
pubmed: 31405895
Nat Immunol. 2020 Aug;21(8):914-926
pubmed: 32424363
Oncogene. 2020 Feb;39(8):1652-1664
pubmed: 31740782
Nat Immunol. 2022 Apr;23(4):543-555
pubmed: 35288714
Br J Dermatol. 2003 Nov;149 Suppl 66:9-14
pubmed: 14616338
Science. 2019 Mar 8;363(6431):
pubmed: 30846571
Transl Res. 2015 Jul;166(1):89-102
pubmed: 25583444
Oncology. 2008;74(1-2):69-75
pubmed: 18544997
Cancer Immunol Res. 2017 Aug;5(8):676-684
pubmed: 28674082
Cancers (Basel). 2020 Jul 04;12(7):
pubmed: 32635472
Expert Rev Vaccines. 2011 Apr;10(4):463-70
pubmed: 21506644
J Immunol. 2008 Feb 1;180(3):1462-70
pubmed: 18209041
Pharmaceutics. 2022 Oct 25;14(11):
pubmed: 36365103
J Immunol. 2014 Nov 15;193(10):4904-13
pubmed: 25297875
Nat Immunol. 2001 Oct;2(10):947-50
pubmed: 11547333
Science. 2013 Feb 15;339(6121):786-91
pubmed: 23258413
Nat Rev Immunol. 2019 Aug;19(8):477-489
pubmed: 31036962
Cancer Immunol Res. 2019 Nov;7(11):1837-1848
pubmed: 31462408
Front Immunol. 2019 Feb 08;10:168
pubmed: 30800125
PLoS One. 2011 May 03;6(5):e18758
pubmed: 21559281
Sci Rep. 2016 Jan 12;6:19049
pubmed: 26754564
Nature. 2005 Feb 24;433(7028):887-92
pubmed: 15711573
Immunity. 2016 Jan 19;44(1):59-72
pubmed: 26789922
JCI Insight. 2018 Nov 15;3(22):
pubmed: 30429378
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532
Eur J Immunol. 2023 Sep;53(9):e2250123
pubmed: 36724513
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Mol Cell. 2002 Aug;10(2):417-26
pubmed: 12191486
Immunity. 2023 Jan 10;56(1):107-124.e5
pubmed: 36580918
Eur J Immunol. 2012 May;42(5):1226-36
pubmed: 22539295
Nat Commun. 2018 Jun 25;9(1):2463
pubmed: 29941886
Cold Spring Harb Symp Quant Biol. 2013;78:117-24
pubmed: 24092469
Sci Transl Med. 2020 Jun 24;12(549):
pubmed: 32581136
Adv Drug Deliv Rev. 2019 Jul;147:37-43
pubmed: 31302192
Curr Oncol. 2020 Apr;27(Suppl 2):S98-S105
pubmed: 32368179
Cell. 2014 May 22;157(5):1013-22
pubmed: 24855941
Nat Rev Immunol. 2014 Dec;14(12):821-6
pubmed: 25359439
Cell Mol Immunol. 2022 Jan;19(1):14-22
pubmed: 34282297
Oncotarget. 2020 Dec 15;11(50):4607-4612
pubmed: 33400737
J Clin Invest. 2017 Jun 1;127(6):2176-2191
pubmed: 28436934
Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):1637-1642
pubmed: 28137885
Biochem Pharmacol. 2020 May;175:113928
pubmed: 32217101
Cell Rep. 2020 May 5;31(5):107604
pubmed: 32375053
Nature. 2016 Jul 7;535(7610):111-6
pubmed: 27281216
Cancer Discov. 2018 Oct;8(10):1258-1269
pubmed: 30154192
Cancer Res. 2011 Jul 15;71(14):4809-20
pubmed: 21646474
Science. 2021 Nov 26;374(6571):1076-1080
pubmed: 34822265
Immunity. 2016 Apr 19;44(4):924-38
pubmed: 27096321
Int J Cancer. 2003 Dec 10;107(5):773-80
pubmed: 14566827
J Immunol Res. 2021 May 22;2021:9912188
pubmed: 34124272
Science. 2004 Aug 20;305(5687):1153-7
pubmed: 15326355
Leukemia. 2007 Aug;21(8):1691-9
pubmed: 17525722
Int J Cancer. 2012 Aug 15;131(4):E371-81
pubmed: 22020953
J Exp Clin Cancer Res. 2010 Feb 24;29:16
pubmed: 20181250
Immunity. 2023 Oct 10;56(10):2218-2230
pubmed: 37708889
Int J Oncol. 2007 Mar;30(3):631-9
pubmed: 17273764
Cancer Res. 2019 Apr 1;79(7):1465-1479
pubmed: 30482772
Annu Rev Pathol. 2021 Jan 24;16:223-249
pubmed: 33197221
Cell Mol Life Sci. 2022 Mar 16;79(3):191
pubmed: 35292881
J Immunol. 1980 Mar;124(3):1371-7
pubmed: 6153680
J Immunol. 2018 Dec 15;201(12):3759-3769
pubmed: 30420437
Sci Signal. 2021 Apr 27;14(680):
pubmed: 33906973
Hum Vaccin Immunother. 2015;11(2):477-88
pubmed: 25692535
Sci Transl Med. 2020 Oct 14;12(565):
pubmed: 33055241
Immunity. 2017 Oct 17;47(4):697-709.e3
pubmed: 29045901
J Immunol. 2014 Dec 15;193(12):6124-34
pubmed: 25385820
Mol Ther Nucleic Acids. 2019 Mar 1;14:80-89
pubmed: 30583098
Lancet. 2017 Oct 21;390(10105):1833-1842
pubmed: 28855077
Gene Ther. 2005 Jan;12(2):129-39
pubmed: 15483669
Oncogene. 2008 Jan 7;27(2):218-24
pubmed: 18176603
J Exp Med. 2013 Mar 11;210(3):491-502
pubmed: 23460726
Trends Immunol. 2022 Mar;43(3):180-194
pubmed: 35090787
Cell Rep. 2016 Jun 14;15(11):2357-66
pubmed: 27264175
Cell Rep. 2018 Dec 11;25(11):2972-2980.e5
pubmed: 30540933
Nat Rev Immunol. 2020 Sep;20(9):537-551
pubmed: 32203325
Front Immunol. 2018 Jul 19;9:1650
pubmed: 30072995
J Cancer Res Clin Oncol. 2013 Dec;139(12):2097-110
pubmed: 24114287
J Exp Med. 2005 Sep 5;202(5):637-50
pubmed: 16129706